191 related articles for article (PubMed ID: 33049075)
1. C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23.
Roszko KL; Brown S; Pang Y; Huynh T; Zhuang Z; Pacak K; Collins MT
J Bone Miner Res; 2021 Feb; 36(2):315-321. PubMed ID: 33049075
[TBL] [Abstract][Full Text] [Related]
2. Interconnections of fibroblast growth factor 23 and klotho with erythropoietin and hypoxia-inducible factor.
Afsar B; Kanbay M; Afsar RE
Mol Cell Biochem; 2022 Jul; 477(7):1973-1985. PubMed ID: 35381946
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men.
Daryadel A; Bettoni C; Haider T; Imenez Silva PH; Schnitzbauer U; Pastor-Arroyo EM; Wenger RH; Gassmann M; Wagner CA
Pflugers Arch; 2018 Oct; 470(10):1569-1582. PubMed ID: 29961920
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
Noonan ML; Clinkenbeard EL; Ni P; Swallow EA; Tippen SP; Agoro R; Allen MR; White KE
Physiol Rep; 2020 Jun; 8(11):e14434. PubMed ID: 32476270
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Unexplained Mild Hypophosphatemia and Very High Serum FGF23 Concentrations.
Bosman A; Ratsma DM; van der Eerden BC; Zillikens MC
JBMR Plus; 2023 Oct; 7(10):e10790. PubMed ID: 37808399
[
